Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RAINBOW-LTE long-term extension trial of RAY121 in immunological diseases
jRCT2041240131Phase 1Recruiting
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Dec 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 1, open-label, single-arm trial of RAY121 in antiphospholipid syndrome (APS), Bullous Pemphigoid (BP), Behçet's disease (BD) and 3 more, sponsored by Chugai Pharmaceutical Co., Ltd. Primary endpoints: Safety: adverse events and Safety: clinical parameters. Started Dec 2024; status: recruiting.
02
Drugs
RAY121
03
Conditions
antiphospholipid syndrome (APS)Bullous Pemphigoid (BP)Behçet's disease (BD)dermatomyositis (DM)immune-mediated necrotizing myopathy (IMNM)
Beyond the preview
Go deeper on jRCT2041240131.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2041240131.